About this trial
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the first time, an understanding of the shared decision making mechanism of action.
Eligibility criteria
Qualifiers
Ages 18 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified/unspecified schizophrenia spectrum and other psychotic disorders (ICD-10-CM Diagnosis Code F20.x)
Current/past experiences with antipsychotic medications (APM; e.g., currently taking any antipsychotic medication, stopped taking, or considering stopping).
Receive FEP treatment in one of OnTrackNY clinics/sites randomized to intervention or treatment as usual (TAU) - Willing to participate in research interviews after each APM visit during the study period (3 months)
Disqualifiers
Unable to provide informed consent
No experience with APM
Not fluent (speaking, reading, writing) in English
Trial design
Treatments tested in this trial
- The Antipsychotic Medication Decision Aid (APM-DA)
Treatment groups
Locations
Sponsors and collaborators
New York State Psychiatric Institute
Lead sponsor
Temple University
Collaborator